{"name":"Borstkanker Onderzoek Groep","slug":"borstkanker-onderzoek-groep","ticker":"","exchange":"","domain":"","description":"Borstkanker Onderzoek Groep is a specialized research organization focused on advancing breast cancer treatments and improving patient outcomes through clinical trials and innovative research.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Non-Steroidal Aromatase Inhibitor","genericName":"Non-Steroidal Aromatase Inhibitor","slug":"non-steroidal-aromatase-inhibitor","indication":"Treatment of hormone receptor-positive breast cancer","status":"phase_3"},{"name":"Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine","genericName":"Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine","slug":"paclitaxel-bevacizumab-liposomal-doxorubicin-capecitabine","indication":"Metastatic breast cancer (likely indication given Borstkanker Onderzoek Groep focus on breast cancer)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"PTC-Pz","genericName":"PTC-Pz","slug":"ptc-pz","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Non-Steroidal Aromatase Inhibitor","genericName":"Non-Steroidal Aromatase Inhibitor","slug":"non-steroidal-aromatase-inhibitor","phase":"phase_3","mechanism":"Inhibits the enzyme aromatase, which is involved in the production of estrogen.","indications":["Treatment of hormone receptor-positive breast cancer"],"catalyst":""},{"name":"PTC-Pz","genericName":"PTC-Pz","slug":"ptc-pz","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine","genericName":"Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine","slug":"paclitaxel-bevacizumab-liposomal-doxorubicin-capecitabine","phase":"phase_3","mechanism":"This combination regimen uses multiple chemotherapy agents and an anti-angiogenic antibody to kill cancer cells through distinct mechanisms: microtubule stabilization, vascular disruption, DNA intercalation, and antimetabolite activity.","indications":["Metastatic breast cancer (likely indication given Borstkanker Onderzoek Groep focus on breast cancer)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTE50MlRkNlAzUXVXcjN1RjA3M1hQTnpOZDgzSVJldURsMjJNeW9ic2EtdV9TdVJHblZXX2tZX0FVUm1lRE44QkxaVXZWSEFVMUk?oc=5","date":"2023-06-06","type":"pipeline","source":"IKNL","summary":"Slimme inzet van duur medicijn tegen uitgezaaide borstkanker zorgt voor minder bijwerkingen en lagere kosten - IKNL","headline":"Slimme inzet van duur medicijn tegen uitgezaaide borstkanker zorgt voor minder bijwerkingen en lagere kosten","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}